Norris Medicines Ltd.
Snapshot View

7.70 +0.20 ▲2.7%

26 July 2021, 04:00:00 P.M.
Volume: 516

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.norrispharma.com
Financial Indicators
Market Cap 7.70 Cr.
Earnings per share (EPS) -4.96 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share -7.35 Trailing Twelve Months Ending 2021-03
Price to Book Value -1.05 Calculated using Price: 7.70
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.00 Cr. 10,000,700 Shares
FaceValue 10
Company Profile

Norris Medicines is one of the leading Indian manufacturers of Injections and Medicinal formulations. More than two decades of our existence has made us a significant force in production, research and manufacture of medical preparations. Norris in India is a widely recognized name in the manufacturing and export of the best quality medicines and injections. The company is into this business since 1990 and serving human being with our world class products.

Business area of the company

The business area of the company is manufacturing of Injections and Medicinal formulations.

Products of company

The products of the company covers wide range of modern medicinal field such as Antibiotics, Anti Inflammatory, Dermatology, Nutrition, Gastro, Anti malarial, Dental, Diabetic & Cardiac.

Milestones

  • 1992: Launch of Ethical Division and conversion of company into Public Limited company.
  • 1994: WHO cGMP Certificate.
  • 1995: Major Expansions.
  • 1996: Started exporting to European, Middle East, Far East and African Countries.
  • 2006: Launching of Diabetic & Cardiac products.
  • 2007: Launching of Dental product range.
  • 2012: Launching of New Molecule Tolperisone with Paracetamol tablet.
  • 2013: Extension in Anti malarial range with Artemether Lumefantrine tablet & dry syrup.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.67%
1 Week
-3.14%
1 Month
+23.40%
3 Month
-28.37%
6 Month
+28.33%
1 Year
+90.59%
2 Year
-22.61%
5 Year
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 1.00 -1.13 -20.54 -17.93 0.71 -15.52 -76.01 -138.44
Return on Capital Employed (%) 5.08 -0.42 -14.70 3.99 4.06 -4.06 -17.04 -9.18 -18.63
Return on Assets (%) 0.50 -0.48 -7.17 -5.80 0.23 -4.18 -13.07 -9.37 -16.48

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 8 8 6 5 5 5 2 0 -2
Non Curr. Liab. 1 6 5 6 6 6 5 8 11
Curr. Liab. 7 8 8 5 5 10 11 9 8
Minority Int.
Equity & Liab. 16 22 19 17 17 20 18 18 17
Non Curr. Assets 10 10 10 10 10 11 11 10 9
Curr. Assets 6 12 9 7 7 9 8 7 7
Misc. Exp. not W/O
Total Assets 16 22 19 17 17 20 18 18 17

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 16 21 21 19 19 20 14 16 8
Other Income 0 0 0 0 0 0 0 0 0
Total Income 16 21 21 19 19 21 14 16 8
Total Expenditure -14 -20 -22 -17 -18 -21 -15 -17 -10
PBIDT 2 1 -1 2 1 0 -2 -1 -2
Interest 0 0 0 -1 -1 -1 -1 -1 -1
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -1
Taxation -1 1 -1 0 0 1 0 1
Exceptional Items 0
PAT 0 0 -1 -1 0 -1 -3 -2 -3

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 -1 1 1 1 -1 1 -2 -3
Cash Fr. Inv. -1 -1 -2 -1 0 -2 0 0
Cash Fr. Finan. 0 2 0 0 -1 3 -1 2 3
Net Change -1 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 1 1 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 34.04 34.04 10.44 10.44 10.44 34.04 34.04 34.04 34.04
Public 65.96 65.96 89.56 89.56 89.56 65.96 65.96 65.96 65.96
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 26 Jul 2021
Board Meeting Intimation for Approval Of Unaudited Standalone Financial Results Of The Company For The Quarter Ended On 30Th June 2021
NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2021 inter alia to consider and approve Unaudited Standalone Financial Results of the Company for the Quarter ended on 30th June 2021.
Wed, 14 Jul 2021
Shareholding for the Period Ended June 30 2021
Norris Medicines Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 05 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0220
Name of the Signatory :- VINAY RANA
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Mon, 26 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%